BioPharmSignal logoBioPharmSignal

Biotech News

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year

Sarepta Therapeutics (SRPT)Sarepta TherapeuticsCompany update

Recipients include 20 individuals living with Duchenne and five siblings of individuals living with the condition Now in its ninth year, program has awarded more than 150 scholarships CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 8, 2026-- Sarepta Therapeutics, Inc.

Related news

SRPTSarepta Therapeutics2026-09-08 12:59 EST

Sarepta Therapeutics anuncia a los destinatarios de Route 79, el Programa de Becas de Duchenne, para el año académico 2026-2027

SRPTSarepta Therapeutics2026-08-31 20:30 EST

Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

NTLAIntellia2026-09-08 12:00 EST

Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)

NTLAIntellia2026-09-04 12:50 EST

Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million

CRSPCRISPR Therapeutics2026-09-08 12:30 EST

CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

CRSPCRISPR Therapeutics2026-08-28 14:31 EST

CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026

PASGPassage Bio2026-06-24 20:05 EST

Passage Bio and Remix Therapeutics Announce Merger Agreement

ABEOAbeona Therapeutics2026-09-18 11:30 EST

Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)

SGMOSangamo Therapeutics, Inc.2026-08-12 20:01 EST

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

SGMOSangamo Therapeutics, Inc.2026-05-11 20:05 EST

Sangamo Therapeutics Announces First Quarter 2026 Earnings Call

View all latest news

Sarepta Therapeutics

Precision Genetic Medicine Sarepta Therapeutics develops and commercializes genetic medicines for rare neuromuscular diseases, with a major focus on Duchenne muscular dystrophy. ELEVIDYS ELEVIDYS is an AAV-based gene-transfer therapy that delivers a micro-dystrophin transgene to skeletal muscle. It is indicated for ambulatory patients...

Recent company news

SRPTSarepta Therapeutics2026-09-08 13:00 EST

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year

SRPTSarepta Therapeutics2026-09-08 12:59 EST

Sarepta Therapeutics anuncia a los destinatarios de Route 79, el Programa de Becas de Duchenne, para el año académico 2026-2027

SRPTSarepta Therapeutics2026-08-31 20:30 EST

Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

SRPTSarepta Therapeutics2026-08-05 20:05 EST

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

SRPTSarepta Therapeutics2026-07-29 21:00 EST

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
20.67 USD
Market cap
1.72B USD
Exchange
NASDAQ
Sector
Gene Therapy
Location
United States